Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Somatostatin ; related peptides
Reexamination Certificate
2006-10-17
2006-10-17
Campell, Bruce R. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Somatostatin ; related peptides
Reexamination Certificate
active
07122622
ABSTRACT:
The invention relates to a peptide compound having an improved binding affinity to somatostatin receptors, comprising a somatostatin analogue as the peptide and a chelating group covalently linked to the N-terminal free amino group of said peptide, wherein said somatostatin analogue carries an 1-naphthylalanine or a 3-benzothienylalanine residue in its 3-position. The invention further relates to said peptide compound labeled with a detectable element or with a therapeutic radionuclide, as well as to a diagnostic method and to a method for the therapeutic treatment of tumors, by using the labeled compounds.
REFERENCES:
patent: 4853371 (1989-08-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5750499 (1998-05-01), Hoeger et al.
patent: 5821221 (1998-10-01), Shalaby et al.
patent: 5968903 (1999-10-01), Kaneko et al.
patent: 5980945 (1999-11-01), Ruiz
patent: 6204256 (2001-03-01), Shalaby et al.
patent: 6262229 (2001-07-01), Coy et al.
patent: 2003/0114362 (2003-06-01), Gruner et al.
patent: 2004/0102364 (2004-05-01), Bonasera et al.
patent: WO 97/01579 (1997-01-01), None
patent: WO 98/41540 (1998-09-01), None
patent: WO 01/81426 (2001-11-01), None
patent: WO 02/100885 (2002-12-01), None
M. Ginj et al., “Dota-Noc, A High Affinity Ligand for Somatostatin Receptor Subtypes 2, 3 and 5”; Fifth International Electronic Conference on Synthetic Organic Chemistry, Sep. 2001, Internet.
M. Ginj et al., “Dota-Noc, A High Affinity Ligand for Somatostatin Receptor Subtypes 2, 3 and 5”; European Journal of Nuclear Medicine, vol. 28, No. 8, 2001, p. 966.
Rossowski, et al., “Potent Inhibitory Effects of a Type Four Receptor-Selective Somatostatin Analog on Rat Insulin Release”, Biochemical and Biophysical Research Communications, vol. 197, No. 2, Dec. 15, 1993, pp. 366-371, Academic Press, U.S.A.
Reubi, et al., “Affinity Profiles for Human Somatostatin Receptor Subtypes SST1-SST5 of Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use”, European Journal of Nuclear Medicine, vol. 27, No. 3, Mar. 2000, pp. 273-282, Springer-Verlag Heidelberg, Germany.
Fagan, et al., “Insulin Secretion in Inhibited by Subtype Five Somatostatin Receptor in the Mouse”, Surgery, vol. 124, No. 2, Aug. 1998, pp. 254-259, Mosby, Inc., St. Louis, MO.
M. Ginj et al., “Synthesis and Biological Activity of a New and Highly Potent Ligand for Somatostatin Receptors 2, 3 and 5.”, Journal of Peptide Science, vol. 8, No. Supplement, Aug. 2002, pp. S68, John Wiley & Sons, Ltd.
Schmitt et al., “Dota-Noc, a High Affinity Ligand of the Somatostatin Receptor Subtypes Subtypes 2, 3 and 5 for Radiotherapy”, Journal of Labelled Compounds and Radiopharmaceuticals, vol. 44, Supplement 1, May 2001, pp. S697-S699, Switzerland.
Bruns, et al., “Binding Properties of Somatostatin Receptor Subtypes.” Metabolism Clinical and Experimental, vol. 45, No. 8, Suppl. 1, 1996, pp. 17-20.
Lewis, et al., “Synthesis of Somatostatin Analogs Incorporating Nucleo Amino Acids”, Tetrahedron, vol. 50, No. 25, 1994, pp. 7485-7494, Elsevier Science Ltd., Great Britain.
Pinski, et al., “Somatostatin Analog RC-160 and Bombesin/Gastrin-Releasing Peptide Antagonists RC-3095 Inhibit the Growth of Androgen-Independent DU-145 Human Prostate Cancer Line in Nude Mice”, Cancer Letters, vol. 71, No. 1-3, 1993, pp. 189-196, Elsevier Scientific Publishers Ireland Ltd., Ireland.
Ginj Mihaela
Macke Helmut Robert
Reubi Jean-Claude
Schmitt Jörg Simon
BioSynthema Inc.
Campell Bruce R.
Cordero Garcia Marcela M
Thompson & Coburn LLP
LandOfFree
Peptide compounds having improved binding affinity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide compounds having improved binding affinity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide compounds having improved binding affinity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3713946